Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
RXII's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RXII: No Debt )
RXII' s 10-Year Cash to Debt Range
Min: 0.94   Max: No Debt
Current: No Debt

Equity to Asset 0.33
RXII's Equity to Asset is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RXII: 0.33 )
RXII' s 10-Year Equity to Asset Range
Min: -1.04   Max: 0.33
Current: 0.33

-1.04
0.33
Interest Coverage No Debt
RXII's Interest Coverage is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RXII: No Debt )
RXII' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

Z-Score: -5.24
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -5250.38
RXII's Operating margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RXII: -5250.38 )
RXII' s 10-Year Operating margin (%) Range
Min: -13376.29   Max: -5250.38
Current: -5250.38

-13376.29
-5250.38
Net-margin (%) -5244.36
RXII's Net-margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RXII: -5244.36 )
RXII' s 10-Year Net-margin (%) Range
Min: -13278.35   Max: -5244.36
Current: -5244.36

-13278.35
-5244.36
ROE (%) -423.41
RXII's ROE (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RXII: -423.41 )
RXII' s 10-Year ROE (%) Range
Min: -423.41   Max: -423.41
Current: -423.41

ROA (%) -140.08
RXII's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RXII: -140.08 )
RXII' s 10-Year ROA (%) Range
Min: -603.25   Max: -140.08
Current: -140.08

-603.25
-140.08
ROC (Joel Greenblatt) (%) -11835.59
RXII's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RXII: -11835.59 )
RXII' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -11835.59   Max: -3597.18
Current: -11835.59

-11835.59
-3597.18
» RXII's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with RXII



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 14.20
RXII's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RXII: 14.20 )
RXII' s 10-Year P/B Range
Min: 6.12   Max: 14.5
Current: 14.2

6.12
14.5
P/S 87.72
RXII's P/S is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RXII: 87.72 )
RXII' s 10-Year P/S Range
Min: 0   Max: 357
Current: 87.72

0
357
EV-to-EBIT 6.80
RXII's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RXII: 6.80 )
RXII' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 6.8

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.20
RXII's Price/Net Cash is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RXII: 9.20 )
RXII' s 10-Year Price/Net Cash Range
Min: 7.84   Max: 7.84
Current: 9.2

Price/Net Current Asset Value 9.20
RXII's Price/Net Current Asset Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RXII: 9.20 )
RXII' s 10-Year Price/Net Current Asset Value Range
Min: 7.84   Max: 7.84
Current: 9.2

Price/Tangible Book 14.30
RXII's Price/Tangible Book is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RXII: 14.30 )
RXII' s 10-Year Price/Tangible Book Range
Min: 12.08   Max: 12.08
Current: 14.3

Price/Median PS Value 0.60
RXII's Price/Median PS Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RXII: 0.60 )
RXII' s 10-Year Price/Median PS Value Range
Min: 1   Max: 1
Current: 0.6

Business Description

Industry: »
Compare: » details
RXi Pharmaceuticals Corp was incorporated in Delaware as a wholly owned subsidiary of Galena on September 8, 2011 in preparation for its planned spin-off from Galena, which was completed on April 27, 2012. The Company is a biotechnology company. Its main business activities are discovering, developing and commercializing therapies based on its proprietary, new-generation RNA interference platform. Its proprietary therapeutic platform is comprised of novel RNAi compounds, referred to as rxRNA compounds. It has developed a number of unique forms of rxRNA compounds, all of which have been shown to be potent both in vitro and in preclinical in vivo models. These RNAi compounds include rxRNAori and sd-rxRNA, or 'self-delivering' RNA. The Company is subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and specific waste products. It is also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of bio-hazardous materials.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide